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Background. Contrast-induced nephropathy (CIN) often complicates coronary angiography leading to significant morbidity and mortality. The 
pleiotropic effects of statins are thought to be renoprotective, but clinical studies have shown conflicting results. To evaluate the impact of statins on 
CIN in patients undergoing coronary angiography, we conducted a meta-analysis of published trials.
Methods. We searched MEDLINE and EMBASE databases for articles evaluating the effect of statins on the incidence of CIN in patients undergoing 
coronary angiography.
Results. Ten trials involving 32,629 patients were identified (Figure 1). Based on the pooled estimate across the 10 studies, statins reduced 
the incidence of CIN compared to control (OR=0.62, 95% CI: 0.40-0.95, p=0.03). However, when the randomized and non-randomized studies 
were analyzed separately, the beneficial effect of statin pretreatment was no longer evident in the randomized studies (OR=0.76, 95% CI: 0.41-
1.41, p=0.39), although the non-randomized studies showed marginally significant benefit (OR=0.60, 95% CI: 0.36-1.00). There was significant 
heterogeneity among the non-randomized studies (I2=88%, p<0.00001).
Conclusion. Statin pretreatment appears to reduce the incidence of CIN in patients undergoing coronary angiography. However, because of the 
non-randomized nature of most of the studies and the significant heterogeneity among the studies, larger randomized controlled trials are warranted 
to clarify this issue.
